Arcutis Biotherapeutics AI Stock Analysis
Want to see ARQT full AI Analyst Report?
Arcutis Biotherapeutics (ARQT) AI Stock Analysis
Arcutis Biotherapeutics
(NASDAQ:ARQT)
ARQT scores well primarily on improved financial performance (return to profitability, strong cash generation, and low current leverage) and a strongly positive earnings update with raised 2026 revenue guidance and sustained demand momentum. The score is held back by expensive valuation (very high P/E) and technical indicators suggesting the stock is extended/overbought after a strong uptrend.
Arcutis Biotherapeutics (ARQT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.49B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.62M
- Price to Earnings (P/E)
- 118.7
- Beta (1Y)
- 0.59
- Revenue Growth
- 60.00%
- EPS Growth
- ―
- Country
- US
- Employees
- 354
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arcutis Biotherapeutics Business Overview & Revenue Model
Company Description
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has...
Arcutis Biotherapeutics Earnings Call Summary
The call was strongly positive, with robust demand and revenue growth, record quarterly prescriptions, raised 2026 revenue guidance, positive net income and operating cash flow, and progress across commercial, clinical and pipeline initiatives. The main negatives were higher operating expenses, gross-to-net remaining in the low 50s, the timing of expected operating leverage, and the preliminary nature of several pipeline opportunities. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management increased full-year 2026 net revenue guidance to between $535 million and $545 million from the previous range of $525 million to $540 million; for the fourth quarter, it expects substantial sequential demand growth, typical fourth quarter seasonality tailwinds, gross to net discounts to remain stable, minimal pricing-driven sales growth, and expenses to remain at this level, while expecting to maintain positive cash flow through the end of the year. Management expects demand impact from the Skin to Believe In campaign to start being more visible in early 2027, expects the grant rate by dermatology clinicians to remain above 90%, and expects to improve growth and inflect 2027 net sales, with the dramatic shift in operational leverage coming in the latter part of '27 into '28; it also expects a vitiligo readout in the fourth quarter, an HS readout in the first quarter of 2027, and a PDUFA action date on February 23, 2027, for ZORYVE cream 0.05% in infants down to 3 months.
Arcutis Biotherapeutics Financial Statement Overview
Summary
Financials reflect a meaningful turnaround: TTM revenue rose to about $509M with very high gross margins (~90%+) and a shift to positive operating profit, net income (~$30M), and positive free cash flow (~$60M). Balance sheet leverage is low (debt-to-equity ~0.05) with improving equity and positive ROE. The key risk is durability, as losses and negative cash flow were common in recent years and current net margin remains relatively thin (~5.9%).
Income Statement
74PositiveBalance Sheet
82Very PositiveCash Flow
79Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 508.68M | 376.07M | 196.54M | 59.61M | 3.69M | 0 |
| Gross Profit | 463.81M | 339.38M | 177.41M | 54.62M | 2.93M | -763.00K |
| EBITDA | 44.82M | 1.78M | -109.63M | -228.56M | -294.87M | -205.90M |
| Net Income | 29.91M | -16.14M | -140.04M | -262.14M | -311.46M | -206.36M |
Balance Sheet | ||||||
| Total Assets | 524.43M | 432.97M | 348.89M | 341.37M | 449.27M | 408.15M |
| Cash, Cash Equivalents and Short-Term Investments | 259.46M | 220.98M | 227.96M | 271.86M | 409.59M | 388.60M |
| Total Debt | 114.62M | 6.27M | 110.58M | 205.92M | 202.54M | 77.56M |
| Total Liabilities | 280.46M | 243.49M | 191.35M | 252.70M | 239.69M | 110.47M |
| Stockholders Equity | 243.97M | 189.48M | 157.54M | 88.67M | 209.58M | 297.68M |
Cash Flow | ||||||
| Free Cash Flow | 59.71M | -6.31M | -112.30M | -247.49M | -281.00M | -175.62M |
| Operating Cash Flow | 59.96M | -5.63M | -112.16M | -247.06M | -257.71M | -174.63M |
| Investing Cash Flow | -82.82M | -30.25M | 28.82M | 180.23M | -87.20M | -75.95M |
| Financing Cash Flow | 9.23M | 6.97M | 66.20M | 101.32M | 301.80M | 281.95M |
Arcutis Biotherapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARQT, the sentiment is Neutral. The current price of 27.61 is below the 20-day moving average (MA) of 29.60, below the 50-day MA of 27.74, and above the 200-day MA of 25.40, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 46.65 is Neutral, neither overbought nor oversold. The STOCH value of 44.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARQT.
Arcutis Biotherapeutics Risk Analysis
Arcutis Biotherapeutics disclosed 72 risk factors in its most recent earnings report. Arcutis Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksArcutis Biotherapeutics Peers Comparison
Overall Rating
ARQT75Outperform
PVLA64Neutral
MANE50Neutral
ACRS48Neutral
MLTX39Underperform
ALMS30Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $3.46B | 118.65 | 14.18% | ― | 60.00% | ― | |
| 64Neutral | $2.14B | -26.65 | -44.44% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $5.27B | -47.30 | -19.90% | ― | ― | -57.61% | |
| 48Neutral | $555.14M | -6.03 | -59.20% | ― | -59.34% | 57.30% | |
| 39Underperform | $918.30M | -2.93 | -79.95% | ― | ― | -10.20% | |
| 30Underperform | $570.56M | -1.27 | -99.61% | ― | -67.28% | 9.70% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics Inc | 27.61 | 0.28 | 1.02% | |
| PVLA | Palvella Therapeutics, Inc. | 146.58 | 55.04 | 60.13% | |
| ACRS | Aclaris Therapeutics Inc. | 3.50 | 1.09 | 45.23% | |
| MLTX | Moonlake Immunotherapeutics | 10.79 | -2.21 | -17.00% | |
| ALMS | Alumis Inc. | 4.39 | -2.53 | -36.49% | |
| MANE | Veradermics, Incorporated | 124.86 | 87.11 | 230.75% |
Arcutis Biotherapeutics Corporate Events
Arcutis Biotherapeutics Adds Veteran Leader to Board
PositiveOn October 23, 2026, Arcutis Biotherapeutics increased the size of its board of directors from ten to eleven members and appointed veteran pharmaceutical executive Dr. Robert Scott as an independent Class II director, with his term running through th...
Arcutis Biotherapeutics Announces Key Commercial Leadership Changes
PositiveArcutis Biotherapeutics reported strong second-quarter 2026 results, underscoring the momentum of its ZORYVE franchise in immuno-dermatology. Net product revenues climbed to $129.9 million, up 59% year over year and 23% sequentially, supported by ris...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
